Heterocyclic derivatives as metabotropic glutamate receptor modulators
申请人:Merz Pharma GmbH & Co. KGaA
公开号:EP2650284A1
公开(公告)日:2013-10-16
The invention relates to heterocyclic derivatives of formula I as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.
[EN] ACETYLENE DERIVATIVES HAVING MGLUR 5 ANTAGONISTIC ACTIVITY<br/>[FR] DERIVES D'ACETYLENE POSSEDANT UNE ACTIVITE ANTAGONISTE MGLUR 5
申请人:NOVARTIS AG
公开号:WO2003047581A1
公开(公告)日:2003-06-12
The invention provides compounds of formula (I) wherein m, n, A, R, R', R', Ro, X and Y are as defined in the description, and their preparation. The compounds of formula (I) are useful as pharmaceuticals in the treatment of e.g. nervous system disorders.
ACETYLENE DERIVATIVES HAVING MGLUR 5 ANTAGONISTIC ACTIVITY
申请人:Gasparini Fabrizio
公开号:US20130331568A1
公开(公告)日:2013-12-12
The invention provides compounds of formula I
wherein n, A, R, R′, R″, R
0
, X and Y are as defined in the description, and their preparation. The compounds of formula I are useful as pharmaceuticals.
Acetylene derivatives having mglur 5 antagonistic activity
申请人:Gasparini Fabrizio
公开号:US20050065191A1
公开(公告)日:2005-03-24
The invention provides compounds of formula (I) wherein m, n, A, R, R′, R″, R
0
, X and Y are as defined in the description, and their preparation. The compounds of formula (I) are useful as pharmaceuticals in the treatment of e.g. nervous system disorders.
Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators
申请人:Bennani L. Youssef
公开号:US20060079567A1
公开(公告)日:2006-04-13
The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are hexahydroazepinoindole and octahydroazepinoindole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).